![American Society of Clinical Oncology American Society of Clinical Oncology](https://54d4f314-8f94-415c-acb7-fd0a6332f070.s3.amazonaws.com/403/403__asco-logo-lg__274272709.png?X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIAU2BE4PNFKE2WZV7V%2F20240727%2Fus-east-1%2Fs3%2Faws4_request&X-Amz-Date=20240727T013251Z&X-Amz-SignedHeaders=host&X-Amz-Expires=86400&X-Amz-Signature=b49619017e03fdf23dfe65198242559940592f3be991e0a270d795352f9d0ca2)
Pancreatic Cancer - Evaluating Susceptibility
Key Points
Key Points
- Assessment of risk should include a comprehensive review of family history of cancer.
Assessment
...sessment
...ical evaluations of people (with or without panc...
...uals with a family history of pancreatic cancer...
...c risk evaluation should be conducted in conj...
...patients diagnosed with pancreatic adenoca...
...individual with a cancer diagnosis...
...netic testing in a patient with pan...
...s have been linked to risk for pancreati...
...ancer surveillance can be considered for indivi...
...not yet consensus on pathologic targets for su...
...otential risks of surveillance including the ris...
...currently a lack of consensus regarding which...
...enes Associated with Increased Risk for Pancre...